vs
CATHAY GENERAL BANCORP（CATY）与REPLIGEN CORP（RGEN）财务数据对比。点击上方公司名可切换其他公司
CATHAY GENERAL BANCORP的季度营收约是REPLIGEN CORP的1.1倍（$222.8M vs $197.9M），CATHAY GENERAL BANCORP净利率更高（653.4% vs 6.7%，领先646.7%），CATHAY GENERAL BANCORP同比增速更快（19.5% vs 13.6%），CATHAY GENERAL BANCORP自由现金流更多（$363.7M vs $17.6M），过去两年REPLIGEN CORP的营收复合增速更高（14.4% vs 12.8%）
国泰万通金控是总部位于美国的银行控股公司，旗下运营国泰银行，面向亚裔社区、中小企业提供个人及商业存贷款、财富管理等金融服务，业务覆盖加州、纽约、得州等美国多州及部分亚洲市场。
Repligen是一家全球生命科学企业，专注于创新生物工艺技术与系统的研发及商业化，助力提升生物药生产效率。公司1981年成立，总部位于美国马萨诸塞州沃尔瑟姆，于纳斯达克挂牌上市，股票代码RGEN，截至2025年全球员工超1900人，主要服务生物制药领域客户。
CATY vs RGEN — 直观对比
营收规模更大
CATY
是对方的1.1倍
$197.9M
营收增速更快
CATY
高出5.8%
13.6%
净利率更高
CATY
高出646.7%
6.7%
自由现金流更多
CATY
多$346.1M
$17.6M
两年增速更快
RGEN
近两年复合增速
12.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $222.8M | $197.9M |
| 净利润 | $90.5M | $13.3M |
| 毛利率 | — | 52.5% |
| 营业利润率 | 50.9% | 9.0% |
| 净利率 | 653.4% | 6.7% |
| 营收同比 | 19.5% | 13.6% |
| 净利润同比 | 12.9% | 143.9% |
| 每股收益（稀释后） | $1.33 | $0.24 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CATYRGEN
| Q4 25 | $222.8M | $197.9M | ||
| Q3 25 | $210.6M | $188.8M | ||
| Q2 25 | $196.6M | $182.4M | ||
| Q1 25 | $187.8M | $169.2M | ||
| Q4 24 | $186.5M | $174.1M | ||
| Q3 24 | $189.5M | $154.9M | ||
| Q2 24 | $178.5M | $154.1M | ||
| Q1 24 | $175.2M | $151.3M |
净利润CATYRGEN
| Q4 25 | $90.5M | $13.3M | ||
| Q3 25 | $77.7M | $14.9M | ||
| Q2 25 | $77.5M | $14.9M | ||
| Q1 25 | $69.5M | $5.8M | ||
| Q4 24 | $80.2M | $-30.3M | ||
| Q3 24 | $67.5M | $-654.0K | ||
| Q2 24 | $66.8M | $3.3M | ||
| Q1 24 | $71.4M | $2.1M |
毛利率CATYRGEN
| Q4 25 | — | 52.5% | ||
| Q3 25 | — | 53.2% | ||
| Q2 25 | — | 50.0% | ||
| Q1 25 | — | 53.6% | ||
| Q4 24 | — | 26.1% | ||
| Q3 24 | — | 50.0% | ||
| Q2 24 | — | 49.8% | ||
| Q1 24 | — | 49.5% |
营业利润率CATYRGEN
| Q4 25 | 50.9% | 9.0% | ||
| Q3 25 | 44.5% | 8.9% | ||
| Q2 25 | 49.0% | 7.6% | ||
| Q1 25 | 46.1% | 3.9% | ||
| Q4 24 | 46.5% | -17.7% | ||
| Q3 24 | 41.2% | -5.1% | ||
| Q2 24 | 40.7% | 1.0% | ||
| Q1 24 | 45.7% | 1.3% |
净利率CATYRGEN
| Q4 25 | 653.4% | 6.7% | ||
| Q3 25 | 36.9% | 7.9% | ||
| Q2 25 | 39.4% | 8.2% | ||
| Q1 25 | 37.0% | 3.4% | ||
| Q4 24 | 587.9% | -17.4% | ||
| Q3 24 | 35.6% | -0.4% | ||
| Q2 24 | 37.4% | 2.2% | ||
| Q1 24 | 40.8% | 1.4% |
每股收益（稀释后）CATYRGEN
| Q4 25 | $1.33 | $0.24 | ||
| Q3 25 | $1.13 | $0.26 | ||
| Q2 25 | $1.10 | $0.26 | ||
| Q1 25 | $0.98 | $0.10 | ||
| Q4 24 | $1.11 | $-0.55 | ||
| Q3 24 | $0.94 | $-0.01 | ||
| Q2 24 | $0.92 | $0.06 | ||
| Q1 24 | $0.98 | $0.04 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $767.6M |
| 总债务越低越好 | $119.1M | $542.2M |
| 股东权益账面价值 | $2.9B | $2.1B |
| 总资产 | $24.2B | $2.9B |
| 负债/权益比越低杠杆越低 | 0.04× | 0.26× |
8季度趋势，按日历期对齐
现金及短期投资CATYRGEN
| Q4 25 | — | $767.6M | ||
| Q3 25 | — | $748.7M | ||
| Q2 25 | — | $708.9M | ||
| Q1 25 | — | $697.2M | ||
| Q4 24 | — | $757.4M | ||
| Q3 24 | — | $784.0M | ||
| Q2 24 | — | $809.1M | ||
| Q1 24 | — | $780.6M |
总债务CATYRGEN
| Q4 25 | $119.1M | $542.2M | ||
| Q3 25 | $119.1M | $537.9M | ||
| Q2 25 | $119.1M | — | ||
| Q1 25 | $119.1M | — | ||
| Q4 24 | $119.1M | $525.6M | ||
| Q3 24 | $119.1M | — | ||
| Q2 24 | $119.1M | — | ||
| Q1 24 | $119.1M | — |
股东权益CATYRGEN
| Q4 25 | $2.9B | $2.1B | ||
| Q3 25 | $2.9B | $2.1B | ||
| Q2 25 | $2.9B | $2.1B | ||
| Q1 25 | $2.9B | $2.0B | ||
| Q4 24 | $2.8B | $2.0B | ||
| Q3 24 | $2.8B | $2.0B | ||
| Q2 24 | $2.8B | $2.0B | ||
| Q1 24 | $2.8B | $2.0B |
总资产CATYRGEN
| Q4 25 | $24.2B | $2.9B | ||
| Q3 25 | $24.1B | $2.9B | ||
| Q2 25 | $23.7B | $2.9B | ||
| Q1 25 | $23.2B | $2.9B | ||
| Q4 24 | $23.1B | $2.8B | ||
| Q3 24 | $23.3B | $2.8B | ||
| Q2 24 | $23.2B | $2.9B | ||
| Q1 24 | $23.4B | $2.8B |
负债/权益比CATYRGEN
| Q4 25 | 0.04× | 0.26× | ||
| Q3 25 | 0.04× | 0.26× | ||
| Q2 25 | 0.04× | — | ||
| Q1 25 | 0.04× | — | ||
| Q4 24 | 0.04× | 0.27× | ||
| Q3 24 | 0.04× | — | ||
| Q2 24 | 0.04× | — | ||
| Q1 24 | 0.04× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $368.6M | $25.7M |
| 自由现金流经营现金流 - 资本支出 | $363.7M | $17.6M |
| 自由现金流率自由现金流/营收 | 163.2% | 8.9% |
| 资本支出强度资本支出/营收 | 2.2% | 4.1% |
| 现金转化率经营现金流/净利润 | 4.07× | 1.93× |
| 过去12个月自由现金流最近4个季度 | $672.7M | $93.9M |
8季度趋势，按日历期对齐
经营现金流CATYRGEN
| Q4 25 | $368.6M | $25.7M | ||
| Q3 25 | $150.6M | $48.1M | ||
| Q2 25 | $64.0M | $28.6M | ||
| Q1 25 | $99.0M | $15.0M | ||
| Q4 24 | $329.2M | $39.2M | ||
| Q3 24 | $81.2M | $49.3M | ||
| Q2 24 | $72.9M | $42.2M | ||
| Q1 24 | $88.2M | $44.7M |
自由现金流CATYRGEN
| Q4 25 | $363.7M | $17.6M | ||
| Q3 25 | $150.1M | $43.4M | ||
| Q2 25 | $62.7M | $21.5M | ||
| Q1 25 | $96.3M | $11.4M | ||
| Q4 24 | $325.5M | $33.6M | ||
| Q3 24 | $80.0M | $42.3M | ||
| Q2 24 | $72.4M | $37.4M | ||
| Q1 24 | $87.3M | $36.4M |
自由现金流率CATYRGEN
| Q4 25 | 163.2% | 8.9% | ||
| Q3 25 | 71.3% | 23.0% | ||
| Q2 25 | 31.9% | 11.8% | ||
| Q1 25 | 51.2% | 6.8% | ||
| Q4 24 | 174.6% | 19.3% | ||
| Q3 24 | 42.2% | 27.3% | ||
| Q2 24 | 40.5% | 24.3% | ||
| Q1 24 | 49.8% | 24.0% |
资本支出强度CATYRGEN
| Q4 25 | 2.2% | 4.1% | ||
| Q3 25 | 0.2% | 2.5% | ||
| Q2 25 | 0.6% | 3.9% | ||
| Q1 25 | 1.4% | 2.1% | ||
| Q4 24 | 1.9% | 3.2% | ||
| Q3 24 | 0.6% | 4.5% | ||
| Q2 24 | 0.3% | 3.1% | ||
| Q1 24 | 0.5% | 5.5% |
现金转化率CATYRGEN
| Q4 25 | 4.07× | 1.93× | ||
| Q3 25 | 1.94× | 3.23× | ||
| Q2 25 | 0.83× | 1.92× | ||
| Q1 25 | 1.42× | 2.57× | ||
| Q4 24 | 4.10× | — | ||
| Q3 24 | 1.20× | — | ||
| Q2 24 | 1.09× | 12.70× | ||
| Q1 24 | 1.23× | 21.35× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
